According to Gram Research analysis, Hongjam, a silkworm-derived food, significantly reduced liver damage, inflammation, and scarring in mice with fatty liver disease by modulating three key biological pathways simultaneously. The active ingredient appears to be silk fibroin peptides, which suppressed inflammatory signaling and blocked the scarring process. However, these findings are from laboratory studies in mice, and human clinical trials are needed before Hongjam can be recommended as a treatment for people with metabolic liver disease.
Researchers discovered that Hongjam, a food made from silkworms, may help treat a serious liver disease called MASH (metabolic dysfunction-associated steatohepatitis). In laboratory studies using mice, Hongjam reduced liver damage, decreased inflammation, and slowed scarring of liver tissue. The food works by affecting multiple pathways in the body that control fat storage, swelling, and tissue damage. Scientists found that proteins from silkworm fibroin—the material silkworms use to make silk—appear to be the active ingredient. While these results are promising, human studies are still needed to confirm whether Hongjam could help people with fatty liver disease.
Key Statistics
A 2026 laboratory study published in Frontiers in Nutrition found that Hongjam, a silkworm-derived food, markedly alleviated hepatic injury in mice with metabolic dysfunction-associated steatohepatitis by normalizing plasma biochemical parameters and reducing collagen deposition.
Research reviewed by Gram shows that silk fibroin peptides from Hongjam attenuated NF-κB-mediated inflammatory signaling in macrophages and modulated TGF-β/Smad-associated signaling in human hepatocyte-derived cells, suggesting the mechanism behind its protective effects.
The 2026 study demonstrated that Hongjam suppressed activation of the TGF-β/Smad signaling pathway and improved metabolic stress responses by increasing AMPK phosphorylation, addressing multiple disease mechanisms in fatty liver disease simultaneously.
The Quick Take
- What they studied: Whether a silkworm-based food called Hongjam could reduce liver damage, inflammation, and scarring in mice with a fatty liver disease similar to human MASH
- Who participated: Laboratory mice were given a special diet that causes fatty liver disease, then treated with Hongjam. Scientists also tested silkworm proteins in human liver cells grown in dishes
- Key finding: Hongjam significantly reduced liver injury, lowered inflammation markers, decreased fat buildup, and reduced collagen scarring in the livers of treated mice compared to untreated mice
- What it means for you: This research suggests Hongjam could become a dietary option for people with fatty liver disease, but human clinical trials are necessary before it can be recommended as a treatment. Talk to your doctor before trying new supplements
The Research Details
Scientists used mice with experimentally-induced fatty liver disease to test Hongjam’s effects. They examined liver tissue under a microscope, measured liver damage markers in the blood, and analyzed which genes and proteins were activated or deactivated in liver cells. They also grew human liver cells and immune cells in laboratory dishes and exposed them to silkworm proteins to understand how the food works at a cellular level.
This multi-layered approach—combining whole-animal studies with cellular experiments—helps researchers understand both whether something works and how it works. The mouse model mimics human MASH, a disease where fat accumulates in the liver, causing inflammation and scarring over time.
The researchers focused on three main mechanisms: reducing metabolic stress (how the body handles fat), decreasing inflammation (the body’s harmful swelling response), and blocking fibrosis (the scarring process that damages liver tissue).
Using both animal models and cell cultures allows researchers to identify the specific biological pathways affected by a treatment. This approach is important because it shows not just that something works, but explains the mechanism, which helps predict whether results might translate to humans. Testing in mice first is a standard safety step before human trials
This study was published in Frontiers in Nutrition, a peer-reviewed journal. The research used multiple complementary methods (histology, biochemical testing, genetic analysis, and cell culture) to verify findings from different angles. However, this is laboratory research in mice, not human studies. Results in mice don’t always translate to humans, and the sample size of mice tested was not specified in the abstract. Human clinical trials would be needed to confirm safety and effectiveness in people
What the Results Show
Hongjam treatment markedly improved liver health in mice with fatty liver disease. Microscopic examination of liver tissue showed reduced fat accumulation and less scarring compared to untreated mice. Blood tests measuring liver damage (plasma biochemical parameters) returned to near-normal levels in treated animals.
At the molecular level, Hongjam worked through three main pathways: it reduced activation of TGF-β/Smad signaling (a pathway that triggers scarring), it suppressed NF-κB-mediated inflammation (a major inflammatory pathway), and it improved metabolic stress responses by increasing AMPK phosphorylation and boosting genes involved in burning fat and transporting lipids.
When scientists tested silkworm fibroin peptides (the active proteins from Hongjam) on human liver cells and immune cells grown in dishes, they observed the same anti-inflammatory and anti-scarring effects, suggesting these proteins are responsible for Hongjam’s benefits.
The research identified silk fibroin peptides as the likely active ingredient in Hongjam responsible for its protective effects. These peptides appear to work by modulating multiple disease pathways simultaneously rather than targeting just one mechanism. This multi-target approach may explain why Hongjam was effective at reducing both inflammation and fibrosis, which often occur together in MASH
MASH is a progressive liver disease with limited effective treatments currently available. Most existing therapies target single pathways, whereas Hongjam appears to address multiple mechanisms simultaneously. This multi-axis approach is promising because MASH involves complex interactions between fat metabolism, inflammation, and scarring. The finding that a food-derived compound can modulate these multiple pathways aligns with growing research interest in natural compounds for metabolic liver diseases
This research was conducted entirely in laboratory settings—mice and cell cultures—not in humans. Results in mice frequently don’t translate directly to people due to differences in metabolism and physiology. The study didn’t specify the exact number of mice tested or provide detailed statistical analysis in the abstract. Long-term safety and optimal dosing in humans remain unknown. The MCD diet-induced mouse model, while useful for research, may not perfectly replicate human MASH, which has multiple causes including obesity and metabolic syndrome
The Bottom Line
Based on this laboratory research, Hongjam shows promise as a potential dietary intervention for fatty liver disease, but it is not yet ready for clinical recommendation. Confidence level: Low to Moderate (laboratory evidence only). Anyone with fatty liver disease should continue following their doctor’s current treatment plan and discuss any interest in Hongjam or silkworm-derived products with their healthcare provider before use. Human clinical trials are essential before this can be recommended as a treatment
This research is most relevant to people with MASH or non-alcoholic fatty liver disease (NAFLD), researchers studying metabolic liver diseases, and nutritionists interested in food-based interventions. It may also interest people with metabolic syndrome or obesity, as these conditions increase fatty liver disease risk. This research should not replace medical treatment for existing liver disease
This is early-stage research. Even if human trials begin soon, it typically takes 5-10 years to move from laboratory findings to approved treatments. People should not expect Hongjam to be available as a medical treatment in the near term. Any benefits in humans would likely develop gradually over weeks to months of consistent use, similar to other dietary interventions
Frequently Asked Questions
Can silkworm food treat fatty liver disease in humans?
Laboratory studies show Hongjam reduced liver damage in mice, but human clinical trials haven’t been conducted yet. It shows promise as a potential dietary intervention, but cannot be recommended as a treatment until human research confirms safety and effectiveness. Consult your doctor before trying it
How does Hongjam help the liver?
Hongjam contains silk fibroin peptides that work through three mechanisms: reducing inflammation by blocking NF-κB signaling, preventing scarring by suppressing TGF-β/Smad pathways, and improving how the body handles fat metabolism. This multi-target approach addresses multiple aspects of fatty liver disease simultaneously
Is Hongjam safe to eat?
Hongjam is made from edible silkworms and appears safe in laboratory studies, but human safety data doesn’t exist yet. Long-term effects and optimal dosing in people are unknown. Anyone considering it should discuss it with their healthcare provider, especially if they have liver disease or take medications
When will Hongjam be available as a treatment?
This research is in early stages. Even with promising results, moving from laboratory findings to approved medical treatments typically takes 5-10 years and requires human clinical trials. Hongjam is not currently available as a medical treatment and may never be if human trials don’t support its use
What’s the difference between this mouse study and real human treatment?
Mouse studies show whether something might work and how it works biologically, but mice metabolize substances differently than humans. Results in mice frequently don’t translate to people. Human clinical trials are essential to confirm that Hongjam is safe and effective in actual patients with fatty liver disease
Want to Apply This Research?
- If a user has fatty liver disease and their doctor approves Hongjam use, track weekly liver function markers (ALT and AST enzyme levels from blood tests) and subjective symptoms like fatigue and abdominal discomfort on a 1-10 scale
- Users could log daily Hongjam consumption (amount and time), paired with dietary choices that support liver health (reduced sugar, moderate fat intake, increased vegetables). The app could send reminders for consistent use and prompt reflection on energy levels and digestive symptoms
- Establish a baseline of liver enzyme levels and symptoms before starting. Schedule monthly check-ins with blood work results from the user’s doctor. Track trends over 3-6 months to assess whether the intervention is helping. Compare against the user’s personal baseline rather than expecting dramatic changes, since this is a dietary supplement, not a pharmaceutical
This article summarizes laboratory research in mice and does not constitute medical advice. Hongjam has not been tested in humans and is not approved as a medical treatment. If you have fatty liver disease or MASH, continue following your doctor’s treatment recommendations. Do not start taking Hongjam or any silkworm-derived products without consulting your healthcare provider first. This research is preliminary and results in animals do not guarantee similar effects in humans. Always discuss new dietary supplements with your doctor, especially if you take medications or have existing health conditions.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.